Orchid Pharma Limited — Updates, 19-02-2025: Press Release

Orchid Pharma's Alathur API facility has successfully completed a USFDA inspection, maintaining its status as the only USFDA-approved facility in India for Sterile Cephalosporins. The inspection, conducted from 10 to 18 February 2025, recorded seven minor observations, none related to data integrity, reflecting the facility's adherence to regulatory standards. This achievement underscores the company’s commitment to quality in pharmaceutical manufacturing.

Additionally, the Alathur facility has renewed its EU Good Manufacturing Practice (GMP) certificate, further validating its compliance with European requirements. These milestones bolster Orchid Pharma’s position as a reliable supplier of high-quality antibiotics in global markets. The Managing Director emphasized the company's dedication to maintaining high manufacturing standards and serving international markets effectively. Overall, this outcome enhances Orchid Pharma's competitive edge in the pharmaceutical industry, presenting a positive outlook for future growth and market presence.